Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Active not recruiting 1

Sponsor Class

OTHER 23INDUSTRY 7OTHER_GOV 1NIH 1NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Endocrine 6Gastrointestinal 4Thoracic 1NET 1Gynecologic 1

Conditions

Neuroendocrine Tumors 20Carcinoma, Neuroendocrine 6von Hippel-Lindau Disease 2Pheochromocytoma 2Paraganglioma 2Pancreatic Neoplasms 2Melanoma 2Breast Neoplasms 2Vipoma 1Urogenital Neoplasms 1Urinary Bladder Neoplasms 1Thyroid Neoplasms 1Somatostatinoma 1Small Cell Lung Carcinoma 1Sarcoma 1Prostatic Neoplasms 1Ovarian Neoplasms 1Non functioning pancreatic endocrine tumor 1Neuroectodermal Tumors, Primitive 1Neuroblastoma 1Neoplasms 1Neoplasm Metastasis 1Multiple Myeloma 1Multiple Endocrine Neoplasia Type 1 1Metastatic Digestive System Neuroendocrine Tumor G1 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, T-Cell 1Lymphoma 1Lung Neoplasms 1Leukemia, Lymphocytic, Chronic, B-Cell 1

Interventions

cabozantinib 1X-Rays 1Specimen Handling 1Phantoms, Imaging 1Magnetic Resonance Spectroscopy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Adenoma, Islet Cell × NET × Clear all
NCT03375320 2026-05-01

Testing Cabozantinib in Patients With Advanced Pancreatic Neuroendocrine and Carcinoid Tumors

National Cancer Institute (NCI)

Phase 3 Active not recruiting
298 enrolled 14 charts 1 FDA
EndocrineGastrointestinalNET

Non functioning pancreatic endocrine tumor, Adenoma, Islet Cell, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡